AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Pharmaceutical Companies

654.210

-12.420-1.86%

Number of Gainers:7

Number of Losers:16

Number of Flat:20

PE:- -

High:672.893

Open:666.621

Low:654.193

Close:666.631

Volume:53.15M

Turnover:150.21M

Market Cap:93.81B

Float Cap:90.67B

Loading ...

Australia's Mesoblast Rises on FDA Approval for New Potency Assay for Commercial Ryoncil

Mesoblast - Receives FDA Approval for New Potency Assay for Commercial Ryoncil Product

THOMSON REUTERS

3 ASX Growth Companies With Up To 15% Insider Ownership

Simply Wall St.

Hexcel Poised to Continue to Benefit From its Widebody Aircraft Exposure, RBC Says

MT Newswires Live

Actinogen Xanamia Pivotal Alzheimer’s Disease Trial Completes Final Patient Visit, with Topline Results on Track for November

THOMSON REUTERS

Paradigm Biopharmaceuticals' Knee Osteoarthritis Study Fails to Reach Continuation Threshold

MT Newswires Live

Prescient Therapeutics Raises Around AU$4.8 Million Via Share Purchase Plan, AU$1.2 Million in Shortfall Placement

MT Newswires Live

Prescient Therapeutics Raises A$4.8 Million Via SPP, A$1.2 Million in Placement

Actinogen Medical Completes Final Patient Visit in Alzheimer's Therapy Trial; Shares Up 5%

MT Newswires Live

Dimerix Receives AU$17 Million in Proceeds After Completing Initial Drawdown Under Non-Dilutive Funding Facility

MT Newswires Live

Prescient Therapeutics - Raises A$4.8 Mln Via Spp and A$1.2 Mln in Placement

THOMSON REUTERS

Prescient Therapeutics - Issue Price for Placement and Spp Shares Set at A$0.065 Per Share

THOMSON REUTERS

Immuron Submits Coffee Microcaps Conference Presentation##

TC Energy Sells Mexico Natural Gas Pipeline to Esentia for $399.2 Million

MT Newswires Live

Dimerix Ltd-Waiver of Listing Rule 10.1 Granted

THOMSON REUTERS

Dimerix - Waiver Permits Security Grant to Skiptan Entities Without Shareholder Approval

THOMSON REUTERS

CSL Seqirus to Supply UK with Aujemflu Flu Shot from 2027/28 Season

UK Extends Pandemic Vaccine Purchase Agreement with CSL Seqirus Through 2031

UK Government Strengthens Vaccine Partnership with CSL Seqirus, Introducing World-First Flu Vaccine (Ativc) and Extending Health Security Pandemic Agreement

THOMSON REUTERS

Immutep Plans Reverse Split of Nasdaq-Listed American Depositary Shares

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigeractivity.com/stock/BK7508/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":654.21045,"timestamp":1790920799841,"preClose":666.6309,"halted":0,"volume":53151570,"delay":0,"changeRate":-0.018632,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":-12.420471,"latestTime":"10-02 16:00:00 AEST","open":666.6212,"high":672.893,"low":654.19293,"amount":150213367,"amplitude":0.028052,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1791154800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1790899200000,1790920800000]],"turnoverRate":0.002113,"increases":6,"decrements":17,"flats":19,"marketCap":93808167218.5,"floatMarketCap":90665936927.125},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":672.893,"amplitude":0.028052,"preClose":666.6309,"low":654.19293,"latestPrice":654.21045,"volume":53151570,"delay":0,"open":666.6212,"prevYearClose":644.3692,"prevWeekClose":662.842,"prevMonthClose":689.549,"prevQuarterClose":689.549,"fiveDayClose":662.842,"twentyDayClose":666.366,"sixtyDayClose":493.616,"secType":"PLATE","market":"AU","turnoverRate":0.002113,"marketCap":93808167218.5,"floatMarketCap":90665936927.125,"timestamp":1790920799841,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":7,"down":16,"flat":20},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2669379574","title":"Australia's Mesoblast Rises on FDA Approval for New Potency Assay for Commercial Ryoncil","url":"https://stock-news.laohu8.com/highlight/detail?id=2669379574","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669379574?lang=en_us&edition=fundamental","pubTime":"2026-09-24 08:38","pubTimestamp":1790210283,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Mesoblast rises on FDA approval for new potency assay for commercial Ryoncil** Shares of MesoblastMSB.AXrise as much as 5.1% to A$2.29, their biggest intraday pct gain since August 28","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nL4N45G01P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7501","MSB.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669432383","title":"Mesoblast - Receives FDA Approval for New Potency Assay for Commercial Ryoncil Product","url":"https://stock-news.laohu8.com/highlight/detail?id=2669432383","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669432383?lang=en_us&edition=fundamental","pubTime":"2026-09-24 07:52","pubTimestamp":1790207540,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nTUEBVRFV4:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MSB.AU","BK7508","BK7501","BK4139","BK7067","MESO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669459671","title":"3 ASX Growth Companies With Up To 15% Insider Ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2669459671","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669459671?lang=en_us&edition=fundamental","pubTime":"2026-09-24 03:08","pubTimestamp":1790190481,"startTime":"0","endTime":"0","summary":"As the Australian market opens with a modestly positive outlook, influenced by Wall Street's tech-driven gains and ongoing discussions around interest rates, investors are keenly watching how local technology stocks respond amidst broader economic uncertainties. In this environment, growth companies with high insider ownership can offer unique insights into potential long-term value creation, as insiders typically have a vested interest in the company's success and may provide stability amid...","market":"us","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/7131000-choice1-card/1788935066370","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/7131000-choice1-card/1788935066370"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/diversified-financials/asx-mfg/magellan-financial-group-shares/news/3-asx-growth-companies-with-up-to-15-insider-ownership","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/diversified-financials/asx-mfg/magellan-financial-group-shares/news/3-asx-growth-companies-with-up-to-15-insider-ownership","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7062","WZR.AU","GIVE.AU","IMLC.AU","ZYAU.AU","BBOZ.AU","BK7110","CBO.AU","XJO.AU","BK7508","AV1.AU","IISV.AU","DXN.AU","AR1.AU","E200.AU","XKO.AU","OZR.AU","BK7095","BK7023","OZF.AU","QRE.AU","VAP.AU","STW.AU","QFN.AU","VAS.AU","BK7501","DACE.AU","EIGA.AU","GEAR.AU","IIGF.AU","SKS.AU","SLF.AU","BEAR.AU","BK7096","BK7141","BK7094","BK7017","BK7104","IOZ.AU","BK7142","FRS.AU","PDI.AU","AYA.AU","XAO.AU","P1E.AU","BK7016","AEM.AU","MFG.AU","SPL.AU","BK7043"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669091482","title":"Hexcel Poised to Continue to Benefit From its Widebody Aircraft Exposure, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2669091482","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669091482?lang=en_us&edition=fundamental","pubTime":"2026-09-23 23:29","pubTimestamp":1790177377,"startTime":"0","endTime":"0","summary":"Hexcel (HXL) is poised to continue to benefit from its widebody aircraft exposure, as current widebody fleet dynamics support a strong aftermarket outlook, RBC Capital Markets said in a Tuesday note.R","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HXL","BK4551","ROKT","LU1435385759.SGD","BK4564","HXL.AU","LU1429558221.USD","BOEU","BK4516","IDEF","LU0205194284.USD","ITA","BK4585","LU0205193047.USD","BK7067","LU0162691827.USD","LU0240878834.USD","LU2326559502.SGD","BA","BZZ","BOEG","PPA","MISL","BK4187","FOWF","BK7508","BOED","NATO","LU0240877869.USD","BK4588","IE000M9KFDE8.USD","LU0072461881.USD","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669184485","title":"Actinogen Xanamia Pivotal Alzheimer’s Disease Trial Completes Final Patient Visit, with Topline Results on Track for November","url":"https://stock-news.laohu8.com/highlight/detail?id=2669184485","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669184485?lang=en_us&edition=fundamental","pubTime":"2026-09-23 20:30","pubTimestamp":1790166600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nTUA9K7DYM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","ACW.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669170131","title":"Paradigm Biopharmaceuticals' Knee Osteoarthritis Study Fails to Reach Continuation Threshold","url":"https://stock-news.laohu8.com/highlight/detail?id=2669170131","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669170131?lang=en_us&edition=fundamental","pubTime":"2026-09-23 14:03","pubTimestamp":1790143392,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  said the interim efficacy result for its phase 3 trial of injectable pentosan polysulfate sodium for the treatment of knee osteoarthritis did not reach the threshold required for the study to proceed, according to a Wednesday filing with the Australian bourse.Operational challenges resulted in a \"significant amount of missing data\" that impacted the interim analysis, which was conducted after about 50% of participants reached the day 112 primary efficacy endpoint, the company said.Paradigm is reviewing the available data to better understand the extent of the impact. It expects to disclose the financial and funding implications of the outcome by Sept. 28.The company said it is assessing the implications for its financial position and future operations, including a review of potential trial wind-down costs. It added that \"material uncertainty\" remains over the consequences of the trial outcome and the company's path forward.Paradigm shares will remain suspen","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","PAR.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669179100","title":"Prescient Therapeutics Raises Around AU$4.8 Million Via Share Purchase Plan, AU$1.2 Million in Shortfall Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2669179100","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669179100?lang=en_us&edition=fundamental","pubTime":"2026-09-23 10:15","pubTimestamp":1790129735,"startTime":"0","endTime":"0","summary":"Prescient Therapeutics  raised around AU$4.8 million via its share purchase plan and around AU$1.2 million in the shortfall placement, according to a Wednesday Australian bourse filing.The issue price under the share purchase plan and the placement was AU$0.065 apiece. Around 18.5 million new shares are expected to be issued under the placement.The proceeds will provide additional funding for the continued development of its PTX-100 treatment candidate beyond the first dose optimization committee review.Its shares fell 2% in recent trading on Wednesday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","PTX.AU","BK4139","BK7067","BK4539","LENZ","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669176721","title":"Prescient Therapeutics Raises A$4.8 Million Via SPP, A$1.2 Million in Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2669176721","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669176721?lang=en_us&edition=fundamental","pubTime":"2026-09-23 09:45","pubTimestamp":1790127905,"startTime":"0","endTime":"0","summary":"BRIEF-Prescient Therapeutics Raises A$4.8 Million Via SPP, A$1.2 Million In PlacementSept 23 (Reuters)-Prescient Therapeutics LtdPTX.AX:RAISES A$4.8 MILLION VIA SPP AND A$1.2 MILLION IN PLACEMENTISSUE PRICE FOR PLACEMENT AND SPP SHARES SET AT A$0.065 PER SHAREFurther company coverage:PTX.AX","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nFWN45E0YH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","PTX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669317305","title":"Actinogen Medical Completes Final Patient Visit in Alzheimer's Therapy Trial; Shares Up 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669317305","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669317305?lang=en_us&edition=fundamental","pubTime":"2026-09-23 08:33","pubTimestamp":1790123638,"startTime":"0","endTime":"0","summary":"Actinogen Medical  said it completed the final patient visit in a phase 2b/3 clinical trial of its Xanamem oral therapy for Alzheimer's disease, according to a Wednesday filing with the Australian bourse.Top-line results for the trial remain on track for November, the company said.The company's shares jumped 5% in recent Wednesday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ACW.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669736001","title":"Dimerix Receives AU$17 Million in Proceeds After Completing Initial Drawdown Under Non-Dilutive Funding Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2669736001","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669736001?lang=en_us&edition=fundamental","pubTime":"2026-09-23 08:17","pubTimestamp":1790122651,"startTime":"0","endTime":"0","summary":"Dimerix  confirmed that it completed an initial drawdown under its AU$34 million non-dilutive funding facility, receiving gross proceeds of AU$17 million, according to a Wednesday Australian bourse filing.The remaining AU$17 million is available for drawdown at the firm's election until March 31, 2027, subject to facility terms, the company said.It also confirmed that it was funded through to the delivery of the Action3 phase three trial of its DMX-200 treatment candidate in patients with focal segmental glomerulosclerosis, a rare kidney disease, and continued advancement of the phase two trial of DMX-652 in acute kidney injury.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","DXB.AU","BK7501","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669856173","title":"Prescient Therapeutics - Raises A$4.8 Mln Via Spp and A$1.2 Mln in Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2669856173","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669856173?lang=en_us&edition=fundamental","pubTime":"2026-09-23 08:04","pubTimestamp":1790121883,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nFWN45E0YH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","PTX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669173890","title":"Prescient Therapeutics - Issue Price for Placement and Spp Shares Set at A$0.065 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2669173890","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669173890?lang=en_us&edition=fundamental","pubTime":"2026-09-23 08:04","pubTimestamp":1790121883,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nFWN45E0YH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTX.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669143640","title":"Immuron Submits Coffee Microcaps Conference Presentation##","url":"https://stock-news.laohu8.com/highlight/detail?id=2669143640","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669143640?lang=en_us&edition=fundamental","pubTime":"2026-09-22 18:03","pubTimestamp":1790071393,"startTime":"0","endTime":"0","summary":"Immuron submits Coffee Microcaps Conference presentation##Immuron published an investor presentation tied to CEO Steven Lydeamore’s Coffee Microcaps Conference slot on Sept. 22, 2026.Slides outline Tr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDL4Sqgpx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMC.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669114086","title":"TC Energy Sells Mexico Natural Gas Pipeline to Esentia for $399.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2669114086","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669114086?lang=en_us&edition=fundamental","pubTime":"2026-09-22 15:53","pubTimestamp":1790063628,"startTime":"0","endTime":"0","summary":"TC Energy  has agreed to sell Energia Occidente de Mexico which owns the Guadalajara-Manzanilla Pipeline, to affiliates of Esentia Energy Development for 560 million Canadian dollars .The sale is expected to close in H1 2027, subject to closing conditions and regulatory approvals.The 313-kilometer pipeline moves up to 500 million cubic feet per day of natural gas between Guadalajara supply facilities to electricity plants and factories in Mexico's Colima and Jalisco states.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4566","TRP.AU","TPYP","IE00BMG7P702.HKD","TRP","BK7508","EINC","IE00BD4GTV84.USD","IE00BMG7P587.USD","IE00BMG7P694.USD","IE000WXP2NQ0.USD","MLPX","IE000SL1IH01.SGD","IE00BD4GTW91.USD","BK7067","BK4144","BOIL","IE00BMG7P926.USD","IE00BMG7P819.SGD","IE000HOSIQF4.USD","IE00BD4GTT62.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669115427","title":"Dimerix Ltd-Waiver of Listing Rule 10.1 Granted","url":"https://stock-news.laohu8.com/highlight/detail?id=2669115427","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669115427?lang=en_us&edition=fundamental","pubTime":"2026-09-22 13:46","pubTimestamp":1790055990,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUE3SH9TS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DXB.AU","BK7508","BK7501","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669115404","title":"Dimerix - Waiver Permits Security Grant to Skiptan Entities Without Shareholder Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2669115404","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669115404?lang=en_us&edition=fundamental","pubTime":"2026-09-22 13:46","pubTimestamp":1790055990,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUE3SH9TS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DXB.AU","BK7501","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669196695","title":"CSL Seqirus to Supply UK with Aujemflu Flu Shot from 2027/28 Season","url":"https://stock-news.laohu8.com/highlight/detail?id=2669196695","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669196695?lang=en_us&edition=fundamental","pubTime":"2026-09-22 07:01","pubTimestamp":1790031677,"startTime":"0","endTime":"0","summary":"CSL Seqirus to supply UK with AUJEMFLU flu shot from 2027/28 seasonCSL unit Seqirus secured a UK rollout of its adjuvanted cell-based flu vaccine AUJEMFLU starting in the 2027/28 season.UKHSA extended","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nNDL3qLMg2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","BK7511","BK7501","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669698196","title":"UK Extends Pandemic Vaccine Purchase Agreement with CSL Seqirus Through 2031","url":"https://stock-news.laohu8.com/highlight/detail?id=2669698196","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669698196?lang=en_us&edition=fundamental","pubTime":"2026-09-22 07:01","pubTimestamp":1790031662,"startTime":"0","endTime":"0","summary":"UK extends pandemic vaccine purchase agreement with CSL Seqirus through 2031CSL’s Seqirus unit strengthened its partnership with the UK government, adding AUJEMFLU to the national flu program from 202","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nNDL7ctxHt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","CSL.AU","BK7067","BK7508","BK7511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669196578","title":"UK Government Strengthens Vaccine Partnership with CSL Seqirus, Introducing World-First Flu Vaccine (Ativc) and Extending Health Security Pandemic Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2669196578","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669196578?lang=en_us&edition=fundamental","pubTime":"2026-09-22 07:00","pubTimestamp":1790031600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nTUA7MQBBX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7501","CSL.AU","BK7511","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669195643","title":"Immutep Plans Reverse Split of Nasdaq-Listed American Depositary Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2669195643","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669195643?lang=en_us&edition=fundamental","pubTime":"2026-09-22 05:52","pubTimestamp":1790027561,"startTime":"0","endTime":"0","summary":"Immutep  said it will change the ratio of its Nasdaq-listed American depositary shares  to 1 ADS representing 200 ordinary shares from 1 ADS representing 10 ordinary shares, equivalent to a 1-for-20 ADS reverse split, effective Sept. 28, according to a late Monday statement by the company.The move is intended to help the company regain compliance with Nasdaq's $1 minimum bid-price requirement, following 30 consecutive business days of trading below that threshold.The change will not affect the company's Australian Securities Exchange-listed shares, share capital, cash position or clinical programs, while fractional ADSs will be sold and the proceeds distributed to eligible holders.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7016","BK7067","NQmain","AFG","BK7508","BK4107","ADS.AU","LCLG","BK4117","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":74,"code":"91000000","status":"200"}]}}